CClinicalTrials.gg
Not yet recruitingNCT06661707Updated Oct 28, 2024

Comparative Study Between Ultrasound Guided Quadratus Lumborum Versus Ilioingunial/ Iliohypogastric Nerves Block as Post-operative Analgesia for Patients Undergoing Inguinal Hernia Repair Surgeries

An interventional study of Sonar guided Quadratus Lumborum block and Sonar guided Ilioinguinal/Iliohypogastric block in Post Operative Pain, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Postoperative pain management is becoming an integral part of anesthesia care. Various techniques of pain relief have been designed. We have designed the study for comparison between ultrasound guided quadratus lumborum (QL) block versus Ultrasound-guided ilioinguinal and iliohypogastric nerves (ILI+IHG) block as regard postoperative pain block and opioid consumption in patients undergoing inguinal hernia repair under general anesthesia.

Read the detailed description

In the anesthesia clinic, an informed written consent will be taken from every patient one day before the surgery. Explanation of the visual analogue score (VAS) will be performed. History, clinical examination and routine investigations including; complete blood count (CBC), fasting blood sugar (FBS), liver function test (LFT), kidney function test (KFT), electrocardiogram (ECG), prothrombin time (PT) and activated partial thromboplastin time (aPTT) will be performed to all patients.

In the induction room, an intravenous (IV) 20 gauge cannula will be inserted and premedication will be limited to intravenous (IV) midazolam (0.03 mg/kg).

  • Intra-operative setting:
  • General anesthesia technique:

The patient will be fasting for at least 8 hours preoperatively. A standardized general anesthesia protocol will be used for all patients. General anesthesia will be induced with propofol (1.5-2 mg /kg) and fentanyl (1 µg /kg) with neuromuscular block Atracurium (0.5mg/kg at induction then 0.1mg/kg as maintenance dose. The patient's airway will be maintained using an endotracheal tube. Maintenance of anesthesia will be commenced using isoflurane (1.2%) in a 50% mixture of oxygen in air.

Ventilator Settings: the ventilation will be achieved with a volume-controlled mode ventilation, respiratory rate adjusted according to EtCO2 to range between 30-35 mmHg, a tidal volume of 6-8 ml/kg and mixture of gases in proportion 50% oxygen and 50% air, with PEEP 5 cm H2O using a closed circle system with a total fresh gas flow rate of 3L/min.

All patients will receive Ondansetron 8mg IV as antiemetic prophylaxis. Fentanyl (0.5 µg /kg) will be given for intraoperative rescue analgesia in case of tachycardia (heart rate more than 90 bpm or more than 20% of the base line of the patient) or hypertension (blood pressure more than 139/89mmHg or more than 20% of the base line of the patient) due to intraoperative pain after exclusion of other causes of tachycardia and increased blood pressure. 1 gm paracetamol will be given 30 minutes before skin closure.

Study procedures (The intervention): (The procedure will be done by the most experienced member of the research team) The procedure will be done in the operating rooms (OR) under complete aseptic technique by the most experienced member of the research team. Patients will be randomly allocated by computer generated randomization to one of the two groups according to the used block into

Group A; Quadratus Lumborum block (QL) group Group B; Ilioinguinal/Iliohypogastric block (ILI/IHG) group

Preparations that will be used for each patient are:

  • Sterile towels, sponges, 4-inch gauze packs and povidone iodine 5% for sterilization, sterile gloves and 21gauge 120mm Locoplex Sono Tap cannula (Locoplex@ VYGON, France).
  • The study drugs (commercially available forms) that will be used are:
  • A 20 ml vial of 0.5% (bupivacaine hydrochloride).
  • A 50ml vial of 2% (Lidocaine hydrochloride).

Group A; Quadratus Lumborum block (QL) group (22 patients) :

The patient will be positioned supine with lateral tilt to perform the block, and the transducer will be placed at the level of the anterior superior iliac spine and will be moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed postero-laterally until its posterior border will be visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg.

Group B; Ilioinguinal/Iliohypogastric block (ILI/IHG) group (22 patients):

The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.

After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg.

o Postoperative settings: At the end of the procedure, the residual neuromuscular block will be reversed with injection of neostigmine (0.05 mg/kg) with atropine (0.01 mg/kg intravenous). Endotracheal tube extubation will be done after oral and endotracheal suction, then the patient will be transferred to postoperative anesthesia care unit (PACU).

At the post-anesthesia care unit (PACU) all patients will receive standard protocol of intravenous paracetamol 1 gm every 6 hours for the following 24 hours, and rescue dose of IV pethidine 50 mg if VAS score is ≥3.

If VAS score is ≥3 after 2 hours another dose of pethidine 25mg IM will be given and repeated if VAS score remains ≥3 every 2 hours for 24 hours postoperatively.

In the surgical ward vital signs (heart rate and blood pressure) as well as pain intensity will be assessed every 2 hours for 24 hours postoperatively.

o If local anaesthetic toxicity occurred, cardiovascular and respiratory support and 20% intralipid bolus of 100 ml over 2-3 min will be given.

02

Conditions studied

  • Post Operative Pain
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 44 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Physical Status: ASA (American society of Anesthesiologists) I - II patients.
  • undergoing inguinal hernia repair

Exclusion criteria

Exclusion Criteria:

  • Contraindications to QL block \& ILI+IHG nerve block such as; (Infection at site of injection, allergy to local anesthetic drugs.)
  • Refusal of procedure or participation in the study by patients.
  • Psychiatric illness or uncooperative patient.
  • Coagulopathy, use of anticoagulants or antiplatelet therapy.
  • Chronic analgesic users, drug addicts and alcoholic patients.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Quadratus Lumborum block (QL) group

    Procedure: Sonar guided Quadratus Lumborum block

  • Active comparator
    Ilioinguinal/Iliohypogastric block (ILI/IHG) group

    Procedure: Sonar guided Ilioinguinal/Iliohypogastric block

Interventions

  • ProcedureSonar guided Quadratus Lumborum block

    The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg

  • ProcedureSonar guided Ilioinguinal/Iliohypogastric block

    The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles. After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg

06

What researchers measure

Primary outcomes

  1. The time to the first request of analgesia

    visual analogue score ≥3 by giving pethidine (50 mg IV)

    Time frame: 24 hours postoperative

Secondary outcomes

  1. Total doses of analgesia

    (pethidine)

    Time frame: 24 hours postoperative

  2. occurence of side effects

    nausea, vomiting,hypotension and bradycardia

    Time frame: 24 hours postoperative

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06661707
Lead sponsor
Ain Shams University
Responsible party
RAMY AHMED (Assistant Professor of Anesthesia, Ain Shams University) — Principal investigator
First posted
Oct 28, 2024
Start date
Oct 30, 2024 (estimated)
Primary completion
May 30, 2025 (estimated)
Completion
May 30, 2025 (estimated)
Last update
Oct 28, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion